Our studies showed that the concentration of IL-22 in the serum of women with ovarian cancer was statistically significantly higher than that in the control group, which proves the participation of this cytokine in pro-cancer immune response through direct and indirect influence involving the immune system cells participating in the regulation of inflammation. This evidence concerns the gene IL22 and cancer.